The Insulin Affordability Crisis: A Policy Proposal to Protect Minnesotans
The increasing prevalence of diabetes mellitus creates serious economic and health burdens for the state of Minnesota, which have been exacerbated by rising insulin prices. Factors contributing to cost increases include the controversial negotiations between pharmaceutical manufacturers and insurance companies, the lack of price transparency, and the scarcity of generic insulin options. This proposal recommends that Minnesota Legislature create a Prescription Drug Cost Review Board and Stakeholder Advisory Council to monitor drug prices and set statewide upper payment limits. This policy will protect Minnesotans from the undue burden of rising medication costs.
Copyright (c) 2020 David Marshall, Keelia Silvis, Mary Gilbertson, Yanyan Chen, Jose Huape
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the Public Health Review are distributed with a Creative Commons Noncommercial Attribution license (CC BY-NC 4.0). This means that each author holds the copyright to their work, and grants users the rights to: share (copy and/or redistribute the material in any medium or format) or adapt (remix, transform, and/or build upon the material) the article, as long as the original author and source are cited, and the use is for noncommercial purposes. Permission is not needed for these noncommercial uses. Read the summary terms, or the full legal license code.